Scholten, David

Publishing since 2004 (Junior)

Has published 5 publications in 6 years

Number of publications published per year by Scholten, David. (Source : PubMed)

Distribution of publications types for Scholten, David. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, Berres ML, Zimmermann H, Streetz KL, Tacke F, Hillebrandt S, Schmitz P, Keppeler H, Berg T, Dahl E, Gassler N, Friedman SL, Trautwein C. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans.  Gastroenterology  2009;137;1  
•  Schnabl B, Scholten D, Brenner DA. What is the potential role of antifibrotic agents for the treatment of liver disease?  Nature clinical practice. Gastroenterology & hepatology  2008;5;9  
•  Wasmuth HE, Zaldivar MM, Berres ML, Werth A, Scholten D, Hillebrandt S, Tacke F, Schmitz P, Dahl E, Wiederholt T, Hellerbrand C, Berg T, Weiskirchen R, Trautwein C, Lammert F. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection.  J. Hepatol.  2008;48;2  
•  Yagmur E, Schnyder B, Scholten D, Schirin-Sokhan R, Koch A, Winograd R, Gressner AM, Trautwein C, Wasmuth HE. [Elevated concentrations of fecal calprotectin in patients with liver cirrhosis]  Dtsch. Med. Wochenschr.  2006;131;36  
•  David ST, Chandran U, Paquette D, Scholten D, Wilson J, Galanis E, Becker M, Crane F, Lester R, Mersereau T, Wong E, Carr D. An observational study of sun and heat protection during Canada Day outdoor celebration, 2003.  Chronic Dis Can  2005;26;2-3  

[ See timeline ] [ See all publications ]